Status:
COMPLETED
Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
Lead Sponsor:
Hospital Regional 1o de Octubre
Collaborating Sponsors:
National Polytechnic Institute, Mexico
Universidad Nacional Autonoma de Mexico
Conditions:
Postmenopausal Osteoporosis
Hypovitaminosis D
Eligibility:
FEMALE
40-78 years
Phase:
NA
Brief Summary
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopaus...
Detailed Description
Participants were selected from the climacteric clinic of the regional hospital "1ro de Octubre-Instituto de Seguridad y Servicios Sociales para Los Trabajadores del Estado (ISSSTE)", Mexico. All part...
Eligibility Criteria
Inclusion
- Participants with a diagnosis of postmenopausal osteoporosis or osteopenia.
- Participants with a diagnosis of hyperparathyroidism or hypovitaminosis D.
- Participants who accepted to participate and that provided informed consent.
Exclusion
- Participants with oncological pathologies.
- Participants with recent fractures.
- Participants with gastric intolerance or hypersensitivity to the drugs.
- Participants were under treatment with another antiresorptive or bone-forming drug, or if they were receiving treatment with thiazide diuretics, lithium, teriparatide or glucocorticoids.
- Participants with Addison's disease, pheochromocytoma or depressive disorders.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 26 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT05346419
Start Date
July 1 2021
End Date
February 26 2022
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE
Mexico City, Mexico, 07300